Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen's Ofman On Value-Based Contracts And Reimbursement Challenges

Executive Summary

Amgen has negotiated 75 value-based contracts – agreements that SVP Josh Ofman sees as one area where biopharma and payer views are aligned. However, tension between the two sides remains high in pricing and reimbursement negotiations when it comes to rebates and other issues.


Related Content

Pharma Executives Need Convincing About Value-Based Contracts
Rx Pricing: Adversaries Search For Common Ground On Value-Based Contracts
Amgen Faces New ICER Roadblock To Repatha Reimbursement
Patient Voice Needed In Outcomes-Based Contracts, PhRMA Exec Says
Enbrel's First Outcomes Contract Is With Harvard Pilgrim; Others May Follow
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
Medicaid Drug Formulary Ideas Floated, But US Manufacturers Are Skeptical
Value-Based Contracts: Relief From Regulatory Barriers In Sight?
'Beautiful baton pass' as Amgen picks up deCODE to validate drug targets


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts